RxDoctor Payments Data

Sara Karam, MD

Clinical Cardiac Electrophysiology · Neptune, NJNPI 1386850774

Payments from drug & device makers

$4,767in general payments, 2019–2025

Across 290 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$607
  • Abbott$565
  • Boehringer Ingelheim$337
  • Pfizer$315
  • Novo Nordisk$310
  • Amgen$280
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,767100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,767 in reported general payments places this provider in the 10th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

See all clinical cardiac electrophysiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$349,986
Medicare patients
778
Services billed
3,345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban198$246,104
XareltoRivaroxaban82$98,193
EntrestoSacubitril/Valsartan36$47,500
Praluent PenAlirocumab27$33,650
Repatha SyringeEvolocumab27$29,711
Repatha SureclickEvolocumab18$22,144
BrilintaTicagrelor23$11,231
FarxigaDapagliflozin Propanediol13$10,872
Flecainide Acetate86$6,352
Dabigatran EtexilateDabigatran Etexilate Mesylate15$5,531
Metoprolol Succinate194$3,719
Rosuvastatin Calcium168$2,761
PradaxaDabigatran Etexilate Mesylate13$2,520
Diltiazem 24hr Er (Cd)Diltiazem Hcl58$2,413
Atorvastatin Calcium164$1,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$315$246,104198 claims
Johnson & JohnsonXarelto$189$98,19382 claims
NovartisEntresto$607$47,50036 claims
AstraZenecaBrilinta, Farxiga$144$22,10336 claims
Boehringer IngelheimPradaxa$337$2,52013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

Other clinical cardiac electrophysiology in Neptune

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →